AbbVie petitions trade commission to ban Alvotech’s Humira biosimilar; Cytokinetics licenses heart drug to Chinese partner

The AbbVie/Alvotech debacle on a Humira biosimilar has taken yet another turn — escalating tensions between the two biotechs.

The pharma giant filed a complaint with the US International Trade Commission on Friday, trying to prevent Alvotech from selling a lower cost version of AbbVie’s Humira,...

Click to view original post